<DOC>
	<DOCNO>NCT00004192</DOCNO>
	<brief_summary>RATIONALE : Colony-stimulating factor may increase number immune cell find bone marrow peripheral blood may help person 's immune system recover side effect chemotherapy . PURPOSE : Randomized phase II trial compare effectiveness filgrastim-SD/01 filgrastim relieve neutropenia follow combination chemotherapy patient non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Colony-Stimulating Factors Relieve Neutropenia Patients With Recurrent Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : I . Compare effect single dose filgrastim-SD/01 vs daily filgrastim ( G-CSF ) duration neutropenia course 1 combination chemotherapy patient recurrent non-Hodgkin 's lymphoma . II . Compare effect regimens duration neutropenia course 2-4 , absolute neutrophil count ( ANC ) course 1-4 , time ANC recovery course 1-4 , safety patient . III . Determine pharmacokinetic profile drug course 1 patient . OUTLINE : This randomize , open label , multicenter study . Patients randomize one two treatment arm . All patient receive etoposide IV 1 hour day 1-4 , cisplatin IV continuously day 1-4 , methylprednisolone IV 15 minute day 1-5 , cytarabine IV 2 hour day 5 . Treatment repeat every 21 day 4 course . Arm I : Patients receive filgrastim-SD/01 subcutaneously ( SQ ) day 6 . Arm II : Patients receive filgrastim ( G-CSF ) SQ daily begin day 6 continue 12 day blood count recover . PROJECTED ACCRUAL : A total 60 patient ( 30 per arm ) accrue study within least 6 month .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis nonHodgkin 's lymphoma ( NHL ) Relapsed disease OR Refractory first line cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) chemotherapy No myelodysplastic syndrome chronic myeloid leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 150,000/mm3 Hepatic : Not specify Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception No prior malignancy except : Curatively treat basal cell squamous cell carcinoma Carcinoma situ cervix Surgically cure malignancy No hypersensitivity E. coli derive product ( e.g. , filgrastim ( GCSF ) , insulin , asparaginase ) PRIOR CONCURRENT THERAPY : Biologic therapy : No prior bone marrow peripheral blood stem cell ( PBSC ) transplantation NHL No prior filgrastimSD/01 No concurrent myelopoietic growth factor No concurrent WBC transfusions No concurrent PBSC collection Chemotherapy : See Disease Characteristics No 2 prior course chemotherapy malignancy Endocrine therapy : No concurrent corticosteroid except topical steroid premedications associate chemotherapy Radiotherapy : At least 4 week since prior radiotherapy Surgery : Not specify Other : At least 72 hour since prior antimicrobial At least 30 day since prior investigational drug No concurrent investigational drug No concurrent prophylactic antibiotic course 1</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>neutropenia</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>